Breaking News
Investing Pro 0
🚨 Our Pro Data Reveals the True Winner of Earnings Season Access Data

Mirati Therapeutics seen worth more than double in a buyout

Stock Markets Nov 23, 2022 17:48
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
 
MRTX
-3.15%
Add to/Remove from a Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
MRK
-0.71%
Add to/Remove from a Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
PFE
-1.32%
Add to/Remove from a Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
BMY
-1.40%
Add to/Remove from a Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
AZN
-3.06%
Add to/Remove from a Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 

By Investing.com Staff

After surging nearly 16% Tuesday on fresh takeover rumors, Mirati Therapeutics (NASDAQ:MRTX) is adding another 5% Wednesday as Wall Street analysts weigh in on the company's takeover prospects and value.

Mirati is said to be attracting renewed takeover interest from large pharma companies ahead of updates on its drug pipeline, Bloomberg News reported, citing people familiar with the matter. Investors are awaiting updated PD1 + adagrasib combination data at next month's ESMO I/O meeting. However, the report added that there are currently no formal bids on the table and a deal isn't imminent.

Analysts weighed in on the report and are bullish on an ultimate deal for the company.

BMO Capital analysts see an upside case of up to $200 per share for Mirati, or more than double the current market price of around $90.

"A takeout is likely to reflect full valuation for usage in the 1L NSCLC setting," they commented. "As we previewed earlier this month, we expect the updated data presented at ESMO I/O to reflect data seen around ASCO in June. Response rates above 50% in PD-1 high/intermediate patients with no liver tox surprises could set up for a potential acquisition."

They added that a takeover accelerates value creation for shareholders. "While Mirati has expressed interest to commercialize on its own, we think an acquisition by a larger BioPharma name with experience in commercializing oncology assets could be a smart move for Mirati, given the competitive nature of the space," they said.

JPMorgan analysts were also bullish on the company's takeover prospects, saying while the reporting would suggest the company regularly considers strategic options and that a deal is not imminent, "[w]ith a handful of potential suitors in scope, we wouldn’t be surprised by a competitive dynamic emerging, particularly on strong KRYSTAL-7 data supporting beneficial ORR and DOR to historical PD1 (-/+ chemo) performance."

They think a takeover could land in the ~$185-200/share range and highlights Merck & Company Inc (NYSE:MRK), Bristol-Myers Squibb (NYSE:BMY), Pfizer (NYSE:PFE), and AstraZeneca (NASDAQ:AZN) as potential suitors.

Mirati Therapeutics seen worth more than double in a buyout
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email